Treatment of Factitious Hyperthyroidism When Anti-Thyroid Drug Therapy Has Not Achieved Euthyroidism

This protocol covers the clinical management step taken in factitious hyperthyroidism after first-line anti-thyroid drug therapy — with beta-blocker support for symptom control — has failed to produce a biochemically euthyroid state, or when relapse occurs after an initial response.

Previous line — failure condition

First-line therapy with anti-thyroid drugs (Carbimazole), supported by beta-blockers (e.g. Propranolol, Atenolol, Metoprolol, or alternatives) for adrenergic symptom control, did not meet the required target: biochemically euthyroid within 4–8 weeks of initiation. Failure to reach this target — or relapse after initial remission — is the trigger for escalation.

Next-line approach (partial overview)

Definitive treatment is the recommended next step in this setting. The clinical goal is normalization of thyroid function tests and meaningful improvement of clinical symptoms within 4–8 weeks. The full protocol specifies the available definitive options and the decision pathway for selecting between them.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1089/thy.2016.0229

In Graves' disease when remission is not achieved with the anti-thyroid drugs or in cases of relapse, definitive treatment is recommended with either radioactive or total thyroidectomy.

If a patient relapses after remission, definitive treatment with Radioactive iodine therapy or total thyroidectomy is recommended.

Most patients respond to radioactive iodine therapy with a normalization of thyroid function tests and improvement of clinical symptoms within 4–8 weeks.

View source ↗